For the many companies in Australia’s medicinal cannabis sector, the health benefits of cannabidiol (CBD) products are self-evident.

But a trial underway in the UK is also testing the safety and efficiency of cannabis-derived medicines to treat infants.

And news outlets this week reported that a newborn boy in Norwich has become the first baby in the world to receive the treatment.

The boy, Oscar Parodi, suffers from neonatal hypoxic-ischemic encephalopathy — a lack of blood flow from the placenta which can cause side effects including brain damage. Parodi was born via emergency Caesarean on March 11 after being three days overdue.

He was transferred to an emergency cooling treatment to protect his brain, where he was also given an intravenous dose of the cannabis-derived drug — all within 12 hours of being born.

Parodi’s treatment is part of a year-long trial, where researchers will prescribe the medicine to infants and check on their progress at 30-day, six-month and 12-month intervals.

The first babies to take part will only be prescribed 1/30th of the usual dose, to allow for the risk of unknown side effects.

Back on home soil, and investors backing the plethora of medicinal cannabis plays on the local market have had a pretty good week.

Of the 34 stocks tracked by Stockhead, 19 posted a weekly gain, while six were unchanged and just nine lost ground.

Compared to the depths of the 2019 cannabis bear market, that’s a strong week and reflects the broader strength across the ASX Small Ords as bullish sentiment continues to hold sway in the wake of the COVID-19 pandemic.

Below is a summary of weekly and annual price performance for ASX-listed cannabis stocks

Scroll or swipe to reveal table. Click headings to sort.

Code Name Price ($) 1Y Tot Ret 1W Tot Ret Market Cap
EVE EVE INVESTMENTS LTD 0.0065 40.0% 40.0% $26.1M
WOA WIDE OPEN AGRICULTURE LTD 0.35 180.8% 35.2% $25.8M
EXL ELIXINOL GLOBAL LTD 0.275 -93.7% 31.8% $50.3M
RGI ROTO-GRO INTERNATIONAL LTD 0.06 -65.7% 30.4% $8.9M
IDT IDT AUSTRALIA LTD 0.18 0.0% 23.3% $44.3M
CAU CRONOS AUSTRALIA LTD 0.135 -74.0% 21.7% $18.0M
CAN CANN GROUP LTD 1.195 -44.8% 20.8% $173.9M
PAL PALLA PHARMA LTD 0.79 -28.2% 20.3% $100.8M
THC THC GLOBAL GROUP LTD 0.38 -13.6% 15.2% $53.4M
MMJ MMJ GROUP HOLDINGS LTD 0.125 -44.7% 13.0% $29.9M
IHL IMPRESSION HEALTHCARE LTD 0.056 180.0% 12.0% $40.8M
EOF ECOFIBRE LTD 3.10 44.7% 5.4% $979.5M
RNO RHINOMED LTD 0.073 -74.3% 1.4% $12.3M
DTZ DOTZ NANO LTD 0.081 27.4% 1.3% $23.4M
YPB YPB GROUP LTD 0.003 -62.5% 0.0% $5.1M
SUD SUDA PHARMACEUTICALS LTD 0.046 -74.1% 0.0% $6.1M
EN1 ENGAGE:BDR LTD 0.01 -75.0% 0.0% $9.2M
LSH LIFESPOT HEALTH LTD 0.033 -60.0% 0.0% $2.6M
MRG MURRAY RIVER ORGANICS GROUP 0.018 -53.2% 0.0% $39.7M
CGB CANN GLOBAL 0.007 -0.8% 0.0% $14.7M
CPH CRESO PHARMA LTD 0.068 -84.9% -1.4% $15.3M
MDC MEDLAB CLINICAL LTD 0.21 -46.3% -2.3% $50.1M
ECS ECS BOTANICS HOLDINGS LTD 0.03 -72.0% -3.4% $14.2M
AGH ALTHEA GROUP HOLDINGS LTD 0.375 -41.7% -3.8% $89.9M
MXC MGC PHARMACEUTICALS LTD 0.025 -54.5% -3.8% $39.3M
BDA BOD AUSTRALIA LTD 0.295 17.6% -4.8% $27.4M
AC8 AUSCANN GROUP HOLDINGS LTD 0.1725 -54.7% -5.6% $53.9M
SCU STEMCELL UNITED LTD 0.0115 -31.3% -8.3% $7.1M
ESE ESENSE-LAB LTD-CDI 0.01 -47.4% -9.1% $1.9M
Wordpress Table Plugin

Cannabis-adjacent stock EVE Investments (ASX:EVE) led the way this week, after jumping by 40 per cent on Tuesday following a positive trading update.

The company said it received a second purchase order out of China for 21,200 units of its raw honey (it also makes a cannabis-honey range), following some strong sales results.

Also having a good week was hemp and medicinal cannabis player Elixinol Global (ASX:EXL), which rose by more than 30 per cent to continue a rollercoaster run over the last three months.

Elixinol’s stock price jumped on Tuesday after announcing it had completed the retail component of its share entitlement offer, raising $5.6m at 20c per share.

The company also said the sale of its Hemp Foods Australia (HFA) subsidiary (for just $500,000) was now off — terminated by the Chinese buyer, which cited COVID-19 impacts.

Elixinol said it would continue to operate HFA, while continuing with its strategy to become a “global Elixinol branded CBD supplements business”.